New York, May 26, 2026, 07:05 (EDT)
TransMedics Group shares edged up before the regular Nasdaq open on Tuesday, quoted at $68.94, about 0.2% above the previous close, as investors returned to a stock still trading on the fallout from its May earnings report. At that level, the organ-transplant technology company had a market value of about $2.5 billion.
The timing matters. Nasdaq was shut on Monday, May 25, for Memorial Day, and its posted core session runs from 9:30 a.m. to 4 p.m. Eastern time; Tuesday’s early move came in premarket trading, the lighter session before the official open.
TransMedics’ own investor page showed no news release later than May 21 and listed the William Blair Growth Stock Conference on June 2 as the next scheduled investor event. That leaves Tuesday’s trading framed by what investors already know: strong sales growth, lower profit, and a margin story that still needs explaining.
The broader tape was mildly supportive. The SPDR S&P 500 ETF Trust, a fund that tracks the S&P 500, was up 0.37%, while the iShares U.S. Medical Devices ETF was up 0.06%, giving TransMedics a firmer but not forceful sector backdrop.
TransMedics’ business rests on the Organ Care System, or OCS, a warm-perfusion platform that keeps donor organs functioning outside the body rather than stored cold and static. Its National OCS Program, or NOP, bundles organ procurement, perfusion management and transplant logistics; the company’s 10-K names OrganOx, now part of Terumo, and XVIVO Perfusion as warm-perfusion rivals, with Paragonix, owned by Getinge, in cold preservation devices.
The May 5 quarter gave both sides material. Revenue rose 21% to $173.9 million and TransMedics kept its 2026 revenue forecast at $727 million to $757 million, but net income fell to $7.3 million from $25.7 million a year earlier; adjusted net income, a non-GAAP figure that excludes specified accounting items, dropped to $10.9 million, or 30 cents a diluted share. Chief Executive Waleed Hassanein called 2026 “another critical period” and said the company was “laser focused” on U.S. heart and lung programs, Europe NOP and OCS Kidney. TransMedics
Margins are the tighter question. Chief Financial Officer Gerardo Hernandez told analysts that management still sees roughly 60% as the right long-term gross margin — profit after direct costs as a share of revenue — and described the first quarter as “more the floor rather than the ceiling.” Investing
Wall Street has already marked down some expectations. On May 6, Canaccord Genuity cut its target to $124 from $152 and kept a buy rating; TD Cowen cut to $120 from $190 and kept buy; Stifel cut to $85 from $130 and kept hold; Piper Sandler cut to $120 from $160 and kept overweight; Needham cut to $142 from $174 and kept buy.
The freshest corporate item was not an operating update. On May 21, TransMedics said it granted options to buy 37,367 shares and 24,848 restricted stock units to 14 employees, including Matthew S. Forsyth, its new senior vice president, general counsel and corporate secretary; inducement grants are equity awards tied to new employees joining the company.
But the downside case is still clear. TransMedics warned in its latest 10-Q that results can swing quarter to quarter, that OCS and NOP expansion, manufacturing scale-up and clinical-trial timing carry risk, and that disclosure controls were not effective as of March 31 because of a material weakness over inventory movement; a material weakness means a control gap that could let a reporting error go undetected in time.
The week ahead is less about one price print than the tone management can set. Investors will be looking for specifics on CHOPS, the heart and lung trial timetable, Europe’s logistics buildout and whether TransMedics can keep revenue growing without giving up more margin.
